Prevagen is a dietary supplement marketed to improve memory and support brain health in aging adults. Its active ingredient is apoaequorin, a calcium-binding protein originally found in the jellyfish Aequorea victoria. Despite heavy advertising and widespread name recognition, the evidence behind Prevagen is thin, and federal regulators have successfully challenged the company’s claims in court.
What Prevagen Claims to Do
Prevagen’s commercials are hard to miss. They feature testimonials from everyday people describing sharper memory after taking the supplement, with taglines like “Healthier brain, better life!” Older ads included a bar graph showing recall-task improvements of 5%, 10%, and 20% over 90 days, though what “recall tasks” meant was never clearly defined. The product is positioned as a daily supplement for adults experiencing age-related memory decline, not as a treatment for Alzheimer’s disease or dementia.
The supplement comes in three strengths: Regular (10 mg of apoaequorin), Extra Strength (20 mg), and Professional Formula (40 mg). All versions also include vitamin D3. It’s sold over the counter at major pharmacies and retailers, typically priced between $30 and $60 for a 30-day supply.
How Apoaequorin Is Supposed to Work
Apoaequorin is a protein that binds calcium. In the jellyfish it comes from, it works alongside green fluorescent protein to produce bioluminescence. The idea behind Prevagen is that because calcium regulation plays a role in brain cell function, supplementing with a calcium-binding protein could support cognitive health.
The problem is biological plausibility. Apoaequorin is a protein, and like virtually all proteins you swallow, it gets broken down during digestion in the gut long before it could reach the brain. Even if fragments survived digestion, there is strong evidence that apoaequorin cannot cross the blood-brain barrier, the tightly controlled membrane that separates your bloodstream from your brain tissue. The Alzheimer’s Drug Discovery Foundation reviewed the available science and concluded that apoaequorin is “unlikely to have any effect on the brain” because it almost certainly never gets there.
What the Clinical Evidence Shows
The main study behind Prevagen’s claims is a trial of 218 older adults (ages 40 to 91) who reported memory concerns. Participants took either 10 mg of apoaequorin or a placebo daily for 90 days. The apoaequorin group showed a 10 to 16% improvement in verbal learning and working memory, while the placebo group improved by a more modest 3 to 8%.
That sounds promising on the surface, but there are significant caveats. Every author on the study was affiliated with Quincy Bioscience, the company that makes Prevagen. No independent research group has replicated these results. The participants had self-reported memory concerns rather than clinically diagnosed impairment, which makes the findings harder to generalize. And federal regulators reviewed the full dataset and came to a very different conclusion about what it actually proved.
The FTC Lawsuit and Court Ruling
In 2017, the Federal Trade Commission and the New York State Attorney General jointly sued Quincy Bioscience, charging that Prevagen’s marketing claims were “false and unsubstantiated.” The agencies argued the company’s own clinical data did not support the advertised benefits, and that the product was not “clinically shown” to improve memory as the ads stated.
The case wound through the courts for years. In late 2024, the FTC announced a win. A federal court issued a memorandum, judgment, and order against the makers of Prevagen, finding that the company’s advertising claims were deceptive. This is one of the more high-profile enforcement actions against a supplement maker in recent years, and it directly undercuts the marketing language that made Prevagen a household name.
Known Side Effects
Prevagen is generally considered low-risk, partly because the protein it contains is likely digested before it can do much of anything. Reported side effects include headache, dizziness, nausea, difficulty sleeping, anxiety, and, ironically, memory problems. In combination products, some users have experienced changes in blood pressure. The overall safety profile of apoaequorin has not been thoroughly established through long-term studies.
Why It Keeps Selling
Prevagen remains one of the best-selling brain supplements in the United States despite the legal rulings and lack of independent evidence. Part of that comes down to the power of repetitive television advertising aimed at older adults who are understandably worried about cognitive decline. The supplement category also operates under looser rules than prescription drugs. Manufacturers don’t need to prove a supplement works before selling it; the burden falls on regulators to prove it doesn’t after it’s already on the market.
If you’re considering Prevagen, the core issue is straightforward: the protein it contains is almost certainly destroyed during digestion and cannot reach your brain. The only clinical trial supporting it was funded and conducted entirely by the manufacturer, and federal courts have ruled the company’s claims deceptive. At $30 to $60 per month, you’re paying a premium for a product whose biological mechanism has no clear path to working.